A Phase 1 interventional study of Selegiline Transdermal Delivery System in Major Depressive Disorder (MDD), sponsored by Corium Innovations, Inc.. Completed at 3 sites in Bulgaria. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Corium Innovations, Inc. (formerly part of Corium, Inc.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Depressive Disorder, Major with a site in Bulgaria — 10 open to participants now, 10 under way, 6 of them phase 3. Depressive Disorder, Major · Bulgaria.
Among the 60 studies in Depressive Disorder, Major with a site in Bulgaria, this one is the 47th largest by enrollment of the 59 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 1, and was the 59th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →10 of the 60 studies in Depressive Disorder, Major with a site in Bulgaria are open now. Recruiting first, the newest first:
Draig Therapeutics Ltd · Sites in Bulgaria, United States, Czechia and 2 more countries
Ages 18–75
Neurocrine Biosciences · Sites in Bulgaria, United States, Australia and 8 more countries
Ages 18+
Seaport Therapeutics · Sites in Bulgaria, United States, Czechia and 4 more countries
Ages 18–65
Neurocrine Biosciences · Sites in Bulgaria, United States, Australia and 20 more countries
Ages 18+
Neurocrine Biosciences · Sites in Bulgaria, United States, Lithuania and 2 more countries
Ages 18+
A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 232 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 470 across the 59 interventional studies, 200 across the 1 observational. Of the 50 that completed or were terminated, 31 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Corium Innovations, Inc., one of the names counted as Corium, Inc.. Under that name alone:
Corium Innovations, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Corium, Inc. has 0 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
6 of the studies in Depressive Disorder, Major with a site in Bulgaria that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT06911112Phase 3Neurocrine BiosciencesNBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
| NCT07065240Seaport TherapeuticsA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | 2027-03 |
| NCT07161700Seaport TherapeuticsAn Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) | 2027-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 60 studies in Depressive Disorder, Major with a site in Bulgaria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The two products used in this study are transdermal patches that contain selegiline. The test drug is the Selegiline Transdermal Delivery System (TDS). The comparator drug is the EMSAM® TDS.
The purpose of this research study is to compare how the skin tolerates the test TDS and the comparator TDS. The study will evaluate and compare skin irritation and possible allergic-type skin reactions (sensitization) caused by the two products.
The comparison will be based on how the skin responds to repeated applications of each TDS. This includes the assessment of skin irritation during the Induction Period and the evaluation of possible allergic or sensitization reactions after the Challenge Period. In addition, the adhesion of each patch (how well the patch sticks to the skin over time) will be regularly checked, as this is important for both product performance and skin safety.
This is a multi-center, evaluator-blinded, randomized phase 1 study evaluating skin irritation and skin sensitization of Selegiline transdermal system in comparison to EMSAM® transdermal patch in healthy volunteers. The study will consist of a 4-week Screening Phase and a Treatment Phase. The Treatment Phase will consist of the following periods: an Induction Period, a Rest Period followed by a Challenge Period and if needed, a Re-Challenge Period.
Trained study staff will examine the patch application sites at scheduled time points and will score any skin reactions using standardized assessment scales. In addition, photographs of the patch application site will be taken to document adhesion status while the patch is being worn.
Furthermore, the overall safety of the test product will be compared with that of the comparator product by monitoring and recording any adverse events, side effects, or discomfort experienced during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Selegiline Transdermal Delivery System
Drug: Selegiline Transdermal Delivery System
1/2 Selegiline TDS patch 6 mg/24 hours and 1/2 EMSAM® patch 6 mg/24 hours will be administered simultaneously
Assessment of irritation
Mean Irritation Score (MIS)
Time frame: From enrollment through the induction, challenge and potential rechallenge phases, up to 15 weeks.
Assessment of sensitization
Number and proportion of subjects sensitized and potentially sensitized to each TDS unit
Time frame: From enrollment through induction, challenge and potential re-challenge phase, up to 15 weeks.
Ran from Aug 2026 to primary completion in Sep 2026, 1 month.
Of 40 industry-sponsored phase 1 interventional studies under Depressive Disorder, Major, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 12. This study's 1 month is below that.
Counting every sponsor, half of 88 studies reached it within 16 months; a quarter within 5 and three quarters within 45.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.